Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph A DeFronzo

Showing results (1-10 of 355) with videos related to

Pageof 36
Sort By:
Diabetes, Obesity & Metabolism|December 16, 2025
Chronically elevated sympathetic nervous system tone: A significant, common, and poorly realised contributor to cardiometabolic disease in type 2 diabetesRalph A DeFronzo
Diabetes|April 2, 2009
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitusRalph A Defronzo
The American Journal of Medicine|March 9, 2010
Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is goingRalph A DeFronzo
The Journal of Clinical Investigation|March 1, 2024
SGLT2 inhibitors: cardiorenal metabolic drugs for the agesRalph A DeFronzo
Diabetes Care|March 31, 2011
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetesRalph A Defronzo
Science Bulletin|January 19, 2023
Chiglitazar: a novel pan-PPAR agonistRalph A DeFronzo
Journal of Diabetes and Its Complications|November 7, 2015
The EMPA-REG study: What has it told us? A diabetologist's perspectiveRalph A DeFronzo
The Medical Clinics of North America|August 17, 2004
Pathogenesis of type 2 diabetes mellitusRalph A DeFronzo
Diabetes, Obesity & Metabolism|April 23, 2017
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitorRalph A DeFronzo
Atherosclerosis. Supplements|July 4, 2006
Is insulin resistance atherogenic? Possible mechanismsRalph A Defronzo
Pageof 36

Showing results (1-10 of 355) with videos related to

Sort By:
Pageof 36
Diabetes, Obesity & Metabolism|December 16, 2025
Chronically elevated sympathetic nervous system tone: A significant, common, and poorly realised contributor to cardiometabolic disease in type 2 diabetesRalph A DeFronzo
Diabetes|April 2, 2009
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitusRalph A Defronzo
The American Journal of Medicine|March 9, 2010
Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is goingRalph A DeFronzo
The Journal of Clinical Investigation|March 1, 2024
SGLT2 inhibitors: cardiorenal metabolic drugs for the agesRalph A DeFronzo
Diabetes Care|March 31, 2011
Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetesRalph A Defronzo
Science Bulletin|January 19, 2023
Chiglitazar: a novel pan-PPAR agonistRalph A DeFronzo
Journal of Diabetes and Its Complications|November 7, 2015
The EMPA-REG study: What has it told us? A diabetologist's perspectiveRalph A DeFronzo
The Medical Clinics of North America|August 17, 2004
Pathogenesis of type 2 diabetes mellitusRalph A DeFronzo
Diabetes, Obesity & Metabolism|April 23, 2017
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitorRalph A DeFronzo
Atherosclerosis. Supplements|July 4, 2006
Is insulin resistance atherogenic? Possible mechanismsRalph A Defronzo
Pageof 36